Literature DB >> 6498197

The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes.

K Nicolay, R J Timmers, E Spoelstra, R Van der Neut, J J Fok, Y M Huigen, A J Verkleij, B De Kruijff.   

Abstract

The interaction of adriamycin with cardiolipin in model membranes and in various membrane preparations derived from rat liver mitochondria was studied and the results are analyzed in the light of a possible specific interaction between adriamycin and cardiolipin. It was found that adriamycin binds to cardiolipin-containing model membranes with a fixed stoichiometry of two drug molecules per cardiolipin. Furthermore, the extent of drug complexation by mitochondria and mitoplasts (inner membrane plus matrix) is in reasonable agreement with their cardiolipin content. In contrast, adriamycin-binding curves of inner membrane ghosts and submitochondrial particles reveal considerable association to an additional site, presumably RNA. The evidence for the potential importance of RNA as a target comes from experiments on outer membranes and microsomes which both appear to bind substantial amounts of adriamycin. Removal of the major part of the RNA associated with these fractions by EDTA treatment is accompanied by a dramatic reduction of binding capacity. We propose that endogenous RNA present in mitochondria and mitoplasts is not accessible for adriamycin at low concentrations of the drug due to the presence of an intact lipid barrier. This potential site comes to expression in ghosts and submitochondrial particles, due to the absence of an intact lipid bilayer and due to the inside-out orientation of the limiting membrane, respectively. Electron microscopical studies show that adriamycin induces dramatic changes in mitochondrial morphology, similar to the uncoupler-induced effects described by Knoll and Brdiczka (Biochim. Biophys. Acta 733, 102-110 (1983). Adriamycin has an uncoupling effect on mitochondrial respiration and oxidative phosphorylation. The concentration dependence of this effect correlates with the adriamycin-binding curve for mitochondria which implies that only bound adriamycin actively inhibits respiration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6498197     DOI: 10.1016/0005-2736(84)90380-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells.

Authors:  C Cullinane; S M Cutts; C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

Review 2.  Functional binding of cardiolipin to cytochrome c oxidase.

Authors:  N C Robinson
Journal:  J Bioenerg Biomembr       Date:  1993-04       Impact factor: 2.945

Review 3.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

Review 4.  Chemotherapy and cardiotoxicity.

Authors:  Howard Broder; Roberta A Gottlieb; Norman E Lepor
Journal:  Rev Cardiovasc Med       Date:  2008       Impact factor: 2.930

Review 5.  Cardiolipins and mitochondrial proton-selective leakage.

Authors:  F L Hoch
Journal:  J Bioenerg Biomembr       Date:  1998-12       Impact factor: 2.945

6.  A new procedure for the preparation of liposomal doxorubicin: biological activity in multidrug-resistant tumor cells.

Authors:  A R Thierry; A Rahman; A Dritschilo
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Rescuing apoptotic neurons in Alzheimer's disease using wheat germ agglutinin-conjugated and cardiolipin-conjugated liposomes with encapsulated nerve growth factor and curcumin.

Authors:  Yung-Chih Kuo; Ching-Chun Lin
Journal:  Int J Nanomedicine       Date:  2015-04-01

Review 8.  Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?

Authors:  Carmelita Abrahams; Nicholas J Woudberg; Sandrine Lecour
Journal:  Lipids Health Dis       Date:  2022-09-01       Impact factor: 4.315

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.